Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone that is secreted in large amounts early in chronic kidney disease. In this cohort, we aimed to investigate the association between serum FGF23 concentration and mortality in patients undergoing peritoneal dialysis (PD).
Methods:
Serum FGF23 level was determined by enzyme-linked immunosorbent assay (ELISA) in a large 15-year prospective cohort study of PD patients with stored serum samples at baseline. Kaplan–Meier survival curves and Cox proportional hazards models were performed to characterise the relationship of FGF23 with mortality.
Results:
A total of 737 incident PD patients were analysed. The baseline median FGF23 concentration was 683.2 (518.5–896.2) pg/mL. Age, serum phosphorus, high-density lipoprotein cholesterol and high-sensitivity C-reactive protein were independently correlated with serum FGF23 concentration. During a median follow-up of 66.7 (41.1–95.4) months, 171 of the 737 participants (23.2%) died, including 84 (49.1%) cardiovascular disease-related and 50 (29.2%) infection-related deaths. Multivariable Cox regression analysis showed that the adjusted hazard ratios of the highest tertile of serum FGF23 compared with those in the lowest tertile were 1.36 (95% confidence interval (CI): 0.89–2.07; p = 0.154), 0.75 (95% CI: 0.40–1.38; p = 0.353) and 2.66 (95% CI: 1.15–6.15; p = 0.022) for all-cause, cardiovascular disease-related and infection-related mortality, respectively.
Conclusion:
High serum FGF23 concentration is associated with a higher risk of infection-related death for incident PD patients.
HuLNapoletanoAProvenzanoM, et al.Mineral bone disorders in kidney disease patients: the ever-current topic. Int J Mol Sci2022; 23(20): 12223.
2.
BlockGAKlassenPSLazarusJM, et al.Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol2004; 15(8): 2208–2218.
3.
WuMWuHHuangX, et al.Associations between serum mineral metabolism parameters and mortality in patients on peritoneal dialysis. Nephrology2019; 24(11): 1148–1156.
4.
WolfM. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol2010; 21(9): 1427–1435.
5.
ShimadaTHasegawaHYamazakiY, et al.FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res2004; 19(3): 429–435.
6.
ShimadaTYamazakiYTakahashiM, et al.Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol2005; 289(5): F1088–F1095.
7.
TakashiYWakinoSMinakuchiM, et al.Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. J Bone Miner Metab2020; 38(1): 70–77.
8.
RossaintJOehmichenJVan AkenH, et al.FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest2016; 126(3): 962–974.
9.
SinghSGrabnerAYanucilC, et al.Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int2016; 90(5): 985–996.
10.
IshigamiJTaliercioJTFeldmanHI, et al.Fibroblast growth factor 23 and risk of hospitalization with infection in chronic kidney disease: the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol2020; 31(8): 1836–1846.
11.
GutierrezOMMannstadtMIsakovaT, et al.Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med2008; 359(6): 584–592.
12.
MarthiADonovanKHaynesR, et al.Fibroblast Growth Factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis. J Am Soc Nephrol2018; 29(7): 2015–2027.
13.
XuLHuXChenW. Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis. J Nephrol2019; 32(2): 307–314.
14.
LiuDZhouSMaoH. MicroRNA-497/fibroblast growth factor-23 axis, a predictive indictor for decreased major adverse cardiac and cerebral event risk in end-stage renal disease patients who underwent continuous ambulatory peritoneal dialysis. J Clin Lab Anal2020; 34(6): e23220.
15.
ZhongZLuoDLuoN, et al.Serum hepcidin-25 and risk of mortality in patients on peritoneal dialysis. Front Med (Lausanne)2021; 8: 684548.
16.
CharlsonMEPompeiPAlesKL, et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40(5): 373–383.
17.
WeinerDETighiouartHVlagopoulosPT, et al.Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol2005; 16(6): 1803–1810.
18.
GehanEAGeorgeSL. Estimation of human body surface area from height and weight. Cancer Chemother Rep1970; 54(4): 225–235.
19.
ZhongZPengFShiD, et al.Serum lipoprotein(a) and risk of mortality in patients on peritoneal dialysis. J Clin Lipidol2020; 14(2): 252–259.
20.
WolfMWhiteKE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens2014; 23(4): 411–419.
21.
Sarmento-DiasMSantos-AraujoCPoinhosR, et al.Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients. Clin Nephrol2016; 85(3): 135–141.
22.
BiSLiangYChengL, et al.Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis. Int Urol Nephrol2017; 49(9): 1653–1659.
23.
NishizawaYHosodaYHorimotoA, et al.Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis. Heart Vessels2021; 36(3): 414–423.
24.
FigurekARrojiMSpasovskiG. FGF23 in chronic kidney disease: bridging the heart and anemia. Cells2023; 12(4): 609.
25.
BieleszBReiterTHammerleFP, et al.The role of iron and erythropoietin in the association of fibroblast growth factor 23 with anemia in chronic kidney disease in humans. J Clin Med2020; 9(8): 2640.
26.
AkalinNOkuturlarYHarmankayaO, et al.Prognostic importance of fibroblast growth factor-23 in dialysis patients. Int J Nephrol2014; 2014(2014): 602034.
27.
OlausonHQureshiARMiyamotoT, et al.Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?Nephrol Dial Transplant2010; 25(9): 3033–3038.
28.
WaziriBMusengeEDuarteR, et al.Associations of plasma fibroblast growth factor 23 and other markers of chronic kidney disease-Mineral and bone disorder with all-cause mortality in South African patients on maintenance dialysis: a 3-year prospective cohort study. PLoS One2019; 14(5): e0216656.
29.
Bouma-de KrijgerAVervloetMG. Fibroblast growth factor 23: are we ready to use it in clinical practice?J Nephrol2020; 33(3): 509–527.
30.
KimHJParkMParkHC, et al.Baseline FGF23 is associated with cardiovascular outcome in incident PD patients. Perit Dial Int2016; 36(1): 26–32.
31.
AsiciogluEVeliogluAArikanH, et al.Baseline carotid intima-media thickness is associated with cardiovascular morbidity and mortality in peritoneal dialysis patients. Ther Apher Dial2021; 25(6): 962–969.
32.
KendrickJCheungAKKaufmanJS, et al.FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol2011; 22(10): 1913–1922.
33.
CzayaBFaulC. FGF23 and inflammation-a vicious coalition in CKD. Kidney Int2019; 96(4): 813–815.
34.
ChoncholMGreeneTZhangY, et al.Low Vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol2016; 27(1): 227–237.
35.
ToroLMicheaLParra-LucaresA, et al.High plasma levels of fibroblast growth factor 23 are associated with increased risk of COVID-19 in end-stage renal disease patients on hemodialysis: results of a prospective cohort. Toxins2023; 15(2): 97.
36.
BacchettaJSeaJLChunRF, et al.Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res2013; 28(1): 46–55.
